PL3842047T3 - Kompozycje hialuronanu o wysokiej elastyczności i sposoby ich zastosowania - Google Patents

Kompozycje hialuronanu o wysokiej elastyczności i sposoby ich zastosowania

Info

Publication number
PL3842047T3
PL3842047T3 PL21156772.2T PL21156772T PL3842047T3 PL 3842047 T3 PL3842047 T3 PL 3842047T3 PL 21156772 T PL21156772 T PL 21156772T PL 3842047 T3 PL3842047 T3 PL 3842047T3
Authority
PL
Poland
Prior art keywords
methods
high elasticity
hyaluronan compositions
hyaluronan
compositions
Prior art date
Application number
PL21156772.2T
Other languages
English (en)
Inventor
Carlos Belmonte
Janet L. Denlinger
Original Assignee
Matrix Biology Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Matrix Biology Institute filed Critical Matrix Biology Institute
Publication of PL3842047T3 publication Critical patent/PL3842047T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
PL21156772.2T 2015-09-24 2016-09-21 Kompozycje hialuronanu o wysokiej elastyczności i sposoby ich zastosowania PL3842047T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562232364P 2015-09-24 2015-09-24

Publications (1)

Publication Number Publication Date
PL3842047T3 true PL3842047T3 (pl) 2024-10-28

Family

ID=57121519

Family Applications (2)

Application Number Title Priority Date Filing Date
PL21156772.2T PL3842047T3 (pl) 2015-09-24 2016-09-21 Kompozycje hialuronanu o wysokiej elastyczności i sposoby ich zastosowania
PL16778947T PL3352766T3 (pl) 2015-09-24 2016-09-21 Kompozycie z hialuronanem o dużej elastyczności i sposoby ich użycia

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL16778947T PL3352766T3 (pl) 2015-09-24 2016-09-21 Kompozycie z hialuronanem o dużej elastyczności i sposoby ich użycia

Country Status (11)

Country Link
US (4) US10383889B2 (pl)
EP (3) EP3352766B1 (pl)
JP (4) JP6948716B2 (pl)
CN (2) CN113577097A (pl)
ES (2) ES2871199T3 (pl)
HU (2) HUE068774T2 (pl)
PL (2) PL3842047T3 (pl)
PT (2) PT3842047T (pl)
RU (2) RU2020123728A (pl)
WO (1) WO2017053339A1 (pl)
ZA (1) ZA202007149B (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180042978A1 (en) * 2008-04-10 2018-02-15 U.S. Nutraceuticals, Llc D/B/A Valensa International Method of treating photo-induced ocular fatigue and associated reduction in speed of ocular focus
EP4137139A1 (en) 2013-07-10 2023-02-22 Matrix Biology Institute Compositions of hyaluronan with high elasticity and uses thereof
WO2017053339A1 (en) 2015-09-24 2017-03-30 Matrix Biology Institute High elasticity hyaluronan compositions and methods of use thereof
CA3080016A1 (en) * 2017-11-22 2019-05-31 Bausch & Lomb Incorporated Ophthalmic viscoelastic compositions
WO2019202017A1 (en) 2018-04-18 2019-10-24 i.com medical GmbH High molecular weight hyaluronic acid for treatment and prevention of severe ocular surface disease
JP7374986B2 (ja) 2018-07-27 2023-11-07 ジョンソン・アンド・ジョンソン・サージカル・ビジョン・インコーポレイテッド 眼を治療するための組成物及び方法
US20200030226A1 (en) 2018-07-27 2020-01-30 Johnson & Johnson Consumer Inc. Botanical and bacterial extracts displaying retinol-like activity
US10966948B2 (en) 2019-07-23 2021-04-06 Johnson & Johnson Surgical Vision, Inc. Compositions and methods for treating the eye
WO2020157570A1 (en) * 2019-01-31 2020-08-06 i.com medical GmbH Hyaluronic acid for relief of idiopathic ocular pain
US11969454B2 (en) 2019-11-19 2024-04-30 Johnson & Johnson Surgical Vision, Inc. Compositions and methods for treating the eye
ES2837548B2 (es) * 2019-12-31 2022-04-18 Univ Miguel Hernandez De Elche Umh Procedimiento y dispositivo para producir una secreción lagrimal refleja y un kit para la medición de la magnitud de flujo lagrimal generado
CN111617313B (zh) * 2020-04-29 2022-09-06 天津医科大学眼科医院 一种眼用线性凝胶在作为临床孔源性视网膜脱离药物方面中的应用
CN116096355A (zh) * 2020-06-12 2023-05-09 I.Com医疗有限责任公司 用于治疗角膜神经损伤或损失的高分子量透明质酸
IT202000025264A1 (it) 2020-10-26 2022-04-26 Innate S R L Composizione iniettabile comprendente acido ialuronico e uso della detta composizione.
US12397017B2 (en) 2022-01-12 2025-08-26 Platform Ophthalmic Innovations, LLC Fortified nutritional lubricating drops for dry eye disease
US11951123B2 (en) 2022-01-12 2024-04-09 Platform Ophthalmic Innovations, LLC Fortified nutritional lubricating drops for dry eye disease

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4141973A (en) 1975-10-17 1979-02-27 Biotrics, Inc. Ultrapure hyaluronic acid and the use thereof
US4407791A (en) 1981-09-28 1983-10-04 Alcon Laboratories, Inc. Ophthalmic solutions
US4517295A (en) 1983-02-18 1985-05-14 Diagnostic, Inc. Hyaluronic acid from bacterial culture
FR2553099B1 (fr) 1983-10-11 1989-09-08 Fidia Spa Fractions d'acide hyaluronique ayant une activite pharmaceutique, procedes pour leur preparation et compositions pharmaceutiques les contenant
IT1198449B (it) 1986-10-13 1988-12-21 F I D I Farmaceutici Italiani Esteri di alcoli polivalenti di acido ialuronico
US5403592A (en) 1987-08-25 1995-04-04 Macnaught Pty Limited Lubricant composition for rheumatism
AU620821B2 (en) 1987-08-25 1992-02-27 Macnaught Pty Limited Hyaluronic acid lubricating compounds
EP0414373B2 (en) 1989-07-24 2001-04-25 Allergan Pharmaceuticals (Ireland) Limited Stable solution of hyaluronate in a balanced salt medium
CA2060223C (en) 1991-02-12 1999-07-20 Clarence C. Lee Injectable medical lubricating fluid composition and method of use
US5234914A (en) 1991-06-11 1993-08-10 Patent Biopharmaceutics, Inc. Methods of treating hemorrhoids and anorecial disease
AU682670B2 (en) 1993-02-05 1997-10-16 Becton Dickinson & Company Syringe needle isolation device
US5631242A (en) 1993-08-04 1997-05-20 Patent Biopharmaceutics, Inc. Hyaluronic acid-urea pharmaceutical compositions utilized for treatment of diseases of cutis
US5607400A (en) 1995-05-19 1997-03-04 Becton, Dickinson And Company Pre-fillable syringe and stopper assembly therefor
IT1277707B1 (it) 1995-12-22 1997-11-11 Chemedica Sa Formulazione oftalmica a base di ialuronato di sodio per uso nella chirurgia oculare
JPH09173450A (ja) 1995-12-26 1997-07-08 Nissho Corp プレフィルドシリンジ
JP3293122B2 (ja) 1996-12-13 2002-06-17 ニプロ株式会社 プレフィルドシリンジ
SE9700827D0 (sv) * 1997-03-07 1997-03-07 Pharmacia & Upjohn Ab Ophthalmic composition
RU2126669C1 (ru) 1997-04-25 1999-02-27 Новокузнецкий государственный институт усовершенствования врачей Способ лечения синдрома сухого глаза
SE9703425D0 (sv) 1997-09-23 1997-09-23 Pharmacia & Upjohn Ab Prefilled ampooules and manufacture thereof
DE19751219A1 (de) 1997-11-19 1999-05-27 Vetter & Co Apotheker Spritze, insbesondere vorgefüllte Spritze, oder Karpule
EP2253549B1 (en) 1998-03-13 2015-03-04 Becton Dickinson and Company Method for manufacturing, filling and packaging medical containers
ITPD980169A1 (it) 1998-07-06 2000-01-06 Fidia Advanced Biopolymers Srl Ammidi dell'acido ialuronico e dei suoi derivati e processo per la loro preparazione.
JP3591636B2 (ja) 2000-04-03 2004-11-24 ニプロ株式会社 プレフィルドシリンジ
ATE250924T1 (de) 2000-04-07 2003-10-15 Medidom Lab Cyklosporin, hyaluronsäure und polysorbate enthaltenes augenarzneimittel
US7635489B2 (en) * 2001-05-18 2009-12-22 Leneau Holdings, Llc Ingestion of hyaluronic acid for improved joint health
JP2003119147A (ja) 2001-10-10 2003-04-23 Raku:Kk ヒアルロン酸化合物の水溶液組成物
EP1480677B8 (en) * 2001-11-21 2012-05-23 Carl Zeiss Meditec SAS Composition for stabilizing hyaluronic acid
US7820194B2 (en) 2001-12-21 2010-10-26 Alcon, Inc. Combinations of viscoelastics for use during surgery
JP4141156B2 (ja) 2002-03-15 2008-08-27 日本ベクトン・ディッキンソン株式会社 プランジャ後退制限機構付きプレフィルドシリンジ
ATE552873T1 (de) 2002-07-02 2012-04-15 Terumo Corp Spritze und vorgefüllte spritze
EP1539193A4 (en) * 2002-07-03 2010-05-05 Pericor Science Inc HYALURONIC ACID COMPOSITIONS AND METHODS OF USE
US7795203B2 (en) 2002-09-30 2010-09-14 Babizhayev Mark A Method for topical treatment of eye disease and composition and device for said treatment
DE10254321A1 (de) 2002-11-21 2004-06-17 Arzneimittel Gmbh Apotheker Vetter & Co. Ravensburg Vorgefüllte Spritze
CA2511217A1 (en) * 2002-12-20 2004-07-15 Chakshu Research, Inc. Ophthalmic formulation for the prevention and treatment of ocular conditions
JP2004229750A (ja) 2003-01-28 2004-08-19 Nipro Corp プレフィルドシリンジ及びそのバレルの製造方法
US20040167480A1 (en) 2003-02-21 2004-08-26 Advanced Medical Optics, Inc. Administration of multiple viscoelastic solutions with a multi-compartment syringe
JP2004262777A (ja) 2003-02-27 2004-09-24 Shiseido Co Ltd アセチル化ヒアルロン酸含有眼用医薬組成物
FR2861734B1 (fr) 2003-04-10 2006-04-14 Corneal Ind Reticulation de polysaccharides de faible et forte masse moleculaire; preparation d'hydrogels monophasiques injectables; polysaccharides et hydrogels obtenus
AR044302A1 (es) 2003-05-13 2005-09-07 Ares Trading Sa Formulaciones con proteinas liquidas estabilizadas en recipientes farmaceuticos
US20050059639A1 (en) 2003-09-11 2005-03-17 Wei Edward T. Ophthalmic compositions and method for treating eye discomfort and pain
US20050075611A1 (en) 2003-10-01 2005-04-07 Hetzler Kevin G. Low extractable, thermoplastic syringe and tip cap
US20090148527A1 (en) 2007-12-07 2009-06-11 Robinson Michael R Intraocular formulation
JP2007536277A (ja) 2004-05-07 2007-12-13 エスケイ ファーマシューティカルズ インコーポレイテッド 安定化されたヒアルロナン調製物及びその方法
US8372814B2 (en) 2004-06-07 2013-02-12 Ista Pharmaceuticals, Inc. Ophthalmic formulations and uses thereof
WO2006073835A2 (en) 2004-12-30 2006-07-13 Genzyme Corporation Regiments for intra-articular viscosupplementation
US9238003B2 (en) 2005-02-04 2016-01-19 Auburn University Extended or continuous wear silicone hydrogel contact lenses for the extended release of comfort molecules
US8388995B1 (en) 2006-02-03 2013-03-05 Auburn University Controlled and extended delivery of hyaluronic acid and comfort molecules via a contact lens platform
ITPD20050056A1 (it) 2005-03-02 2006-09-03 Fidia Farmaceutici Derivati ammidici del'acido ialuronico in osteoartrosi
US7767710B2 (en) 2005-05-25 2010-08-03 Calosyn Pharma, Inc. Method for treating osteoarthritis
DE102005055275A1 (de) * 2005-11-17 2007-05-24 Ursapharm Arzneimittel Gmbh & Co. Kg Phosphatfreie pharmazeutische Zusammensetzung sowie deren Verwendung
US8039447B2 (en) 2005-11-22 2011-10-18 Centre National De La Recherche Scientifique (C.N.R.S.) Derivatives of hyaluronic acid, their preparation process and their uses
US7988675B2 (en) 2005-12-08 2011-08-02 West Pharmaceutical Services Of Delaware, Inc. Automatic injection and retraction devices for use with pre-filled syringe cartridges
CA2633957A1 (en) 2005-12-14 2007-06-21 Anika Therapeutics, Inc. Treatment of arthritis and other musculoskeletal disorders with crosslinked hyaluronic acid
JP4682850B2 (ja) 2006-01-12 2011-05-11 ニプロ株式会社 プレフィルドシリンジ
US20070254841A1 (en) 2006-01-25 2007-11-01 Ophthalmic Research Associates, Inc. Formulations and methods for treating dry eye
US7674781B2 (en) 2006-04-28 2010-03-09 Heather Sheardown Hyaluronic acid-retaining polymers
KR20090053892A (ko) 2006-07-25 2009-05-28 오스모티카 코프. 점안액
EP2059206B8 (en) * 2006-08-28 2012-07-11 Rexaderm, Inc. Dry wound dressing and drug delivery system
ITMI20061668A1 (it) 2006-09-01 2008-03-02 Schiena Michele Giuseppe Di Composizione a base di acido ialuronico e suoi sali per il trattamento di lesioni epiteliali
AU2007320123A1 (en) 2006-11-17 2008-05-22 Agency For Science, Technology And Research Porous polymeric material with cross-linkable wetting agent
WO2008068854A1 (ja) 2006-12-05 2008-06-12 Glycoscience Laboratories, Inc. 変形性関節症の治療剤
FR2918276B1 (fr) 2007-07-02 2010-01-22 Anteis Sa "utilisation d'un gel de polysaccharide(s)naturel(s)pour la preparation d'une formulation injectable de traitement des degenerescences articulaires"
JP2009196903A (ja) 2008-02-19 2009-09-03 Lion Corp 眼科用組成物
US8093365B2 (en) 2008-03-03 2012-01-10 New York University Biocompatible materials containing stable complexes method of TSG-6 and hyaluronan and method of using same
JP5758797B2 (ja) 2008-04-04 2015-08-05 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデイション アルキル化半合成グリコサミノグリカンエーテルならびにその製造および使用方法
FR2938187B1 (fr) * 2008-11-07 2012-08-17 Anteis Sa Composition injectable a base d'acide hyaluronique ou l'un de ses sels, de polyols et de lidocaine, sterilisee a la chaleur
ES2538835T3 (es) 2009-01-07 2015-06-24 Robert John Petrella Tratamiento de lesiones de tejidos blandos utilizando el ácido hialurónico y la toxina botulínica
US20100178317A1 (en) 2009-01-09 2010-07-15 Burke Susan E Lens Care Solutions with Hyaluronic Acid
US8979821B2 (en) 2009-04-14 2015-03-17 Fezza Family Properties, Llc Lacrimal filler
US20100303915A1 (en) 2009-06-02 2010-12-02 Abbott Medical Optics Inc. Therapeutic opthalmic emulsions
AU2010255540A1 (en) 2009-06-05 2012-01-19 Edward Tak Wei Treatment of eye discomfort by topical administration of a cooling agent to the external surface of the eyelid
WO2011031852A1 (en) 2009-09-10 2011-03-17 Boston Foundation For Sight Sodium channel blocker delivery system with scleral lens
CN102781463A (zh) 2009-10-07 2012-11-14 戈诺珍公司 用于皮肤再生的方法和组合物
EP2316420B1 (en) * 2009-10-22 2014-02-26 Consorzio Universitario Unifarm Topical ophthalmic composition to reduce pain
US20110171310A1 (en) * 2010-01-13 2011-07-14 Allergan Industrie, Sas Hydrogel compositions comprising vasoconstricting and anti-hemorrhagic agents for dermatological use
EP3520827B1 (en) * 2010-03-22 2022-05-25 Allergan, Inc. Cross-linked hydrogels for soft tissue augmentation
US20130209531A1 (en) 2010-06-08 2013-08-15 University Of Utah Research Foundation Applications of partially and fully sulfated hyaluronan
CA2809893A1 (en) 2010-09-02 2012-03-08 Mcmaster University Hyaluronic acid-containing biopolymers
PH12013500424B1 (en) 2010-09-10 2018-07-11 Santen Pharmaceutical Co Ltd Agent for treatment of dry eye characterized by combining p2y2 receptor agonist and hyaluronic acid or salt thereof, method for treating dry eye, and use of the p2y2 receptor agonist and hyaluronic acid or salt thereof
JP6047272B2 (ja) 2010-09-15 2016-12-21 テイカ製薬株式会社 角膜上皮障害治療用点眼剤
US8455436B2 (en) 2010-12-28 2013-06-04 Depuy Mitek, Llc Compositions and methods for treating joints
US8524662B2 (en) 2010-12-28 2013-09-03 Depuy Mitek, Llc Compositions and methods for treating joints
US8398611B2 (en) 2010-12-28 2013-03-19 Depuy Mitek, Inc. Compositions and methods for treating joints
US20140088199A1 (en) * 2011-04-05 2014-03-27 Optosolve Llp Ophthalmic treatments
WO2012143876A1 (en) * 2011-04-19 2012-10-26 Anteis S.A. A sterile and injectable aqueous formulation for administration in the intra-articular space of an intra-articular joint
GB201118586D0 (en) 2011-10-27 2011-12-07 Turzi Antoine New A-PRP medical device, manufacturing machine and process
DK2596796T3 (da) * 2011-11-24 2014-01-27 Quimera Ingenieria Biomedica S L Kompleks opnået af hyaluronsyre eller et salt deraf samt chondroitinsulfatblandinger
EP2818172A4 (en) 2012-02-22 2016-02-17 Hyaluronan Res Inst Inc TLR4 MEDIUM, TISSUE HOMEOSTAT, HEPATOCYTE GROWTH FACTOR INDUCTOR, TISSUE-DISAPPEARING AGENT, AND SIRTUINE INDUCTOR WITH HYALURONIC ACID FRAGMENTS AS ACTIVE AGENTS THEREOF
US20150037422A1 (en) 2012-02-22 2015-02-05 Trustees Of Tufts College Compositions and methods for ocular delivery of a therapeutic agent
UA113434C2 (uk) 2012-05-04 2017-01-25 Алкон Рісерч, Лтд. Офтальмологічна композиція з поліпшеним захистом від зневоднювання й утриманням
FR2991876B1 (fr) * 2012-06-13 2014-11-21 Vivacy Lab Composition, en milieu aqueux, comprenant au moins un acide hyaluronique et au moins un sel hydrosoluble de sucrose octasulfate
FR2994846B1 (fr) * 2012-08-29 2014-12-26 Vivacy Lab Composition, sterilisee, comprenant au moins un acide hyaluronique et de l'ascorbyl phosphate de magnesium
CN104981234A (zh) 2013-02-01 2015-10-14 阿勒根公司 包含透明质酸钠和羧甲基纤维素的人工泪液
US9226938B2 (en) 2013-03-14 2016-01-05 RMG Rehabilitation Management Group, LP Combinatorial therapy for treatment of osteoarthritis of the knee
SG11201507724UA (en) * 2013-03-25 2015-10-29 Univ Tokyo Nat Univ Corp Plant cultivation method
ITMI20130883A1 (it) * 2013-05-30 2014-12-01 Eurores S R L Composizioni farmaceutiche comprendenti collagene e sodio ialuronato
EP4137139A1 (en) 2013-07-10 2023-02-22 Matrix Biology Institute Compositions of hyaluronan with high elasticity and uses thereof
EP3071193B1 (en) 2013-11-20 2020-01-08 Panag Pharma Inc. Compositions and methods for treatment of ocular inflammation and pain
CA2931726C (en) 2013-11-25 2022-03-15 Deuteria Biomaterials, Llc Deuterium-enriched hyaluronan
FR3015290B1 (fr) * 2013-12-23 2017-01-13 Lab Vivacy Compositions d'acide hyaluronique compreant de la mepivacaine
WO2017053339A1 (en) 2015-09-24 2017-03-30 Matrix Biology Institute High elasticity hyaluronan compositions and methods of use thereof

Also Published As

Publication number Publication date
US20210085709A1 (en) 2021-03-25
ES2871199T3 (es) 2021-10-28
JP2018529691A (ja) 2018-10-11
EP3352766B1 (en) 2021-03-17
US20170087177A1 (en) 2017-03-30
EP4474011A3 (en) 2025-02-26
PT3352766T (pt) 2022-03-22
EP3842047A1 (en) 2021-06-30
EP3842047B1 (en) 2024-08-07
JP2021165311A (ja) 2021-10-14
JP2026004503A (ja) 2026-01-14
US11583549B2 (en) 2023-02-21
US20250381215A1 (en) 2025-12-18
HK1250657A1 (zh) 2019-01-11
RU2020123728A (ru) 2021-01-18
CN113577097A (zh) 2021-11-02
EP3352766A1 (en) 2018-08-01
JP6948716B2 (ja) 2021-10-13
HUE068774T2 (hu) 2025-01-28
US10888580B2 (en) 2021-01-12
ZA202007149B (en) 2025-04-30
PL3352766T3 (pl) 2021-08-02
HUE054874T2 (hu) 2021-10-28
US20200030364A1 (en) 2020-01-30
JP2023153417A (ja) 2023-10-17
WO2017053339A1 (en) 2017-03-30
EP4474011A2 (en) 2024-12-11
RU2727809C2 (ru) 2020-07-24
ES2990076T3 (es) 2024-11-28
RU2018114926A (ru) 2019-10-24
RU2018114926A3 (pl) 2019-10-24
CN108135926A (zh) 2018-06-08
PT3842047T (pt) 2024-09-19
US10383889B2 (en) 2019-08-20

Similar Documents

Publication Publication Date Title
IL286316A (en) New micro-dystrophins and related method of use
IL274276A (en) CASZ preparations and methods of use
GB2582100B (en) CAS12C Compositions and methods of use
PL3842047T3 (pl) Kompozycje hialuronanu o wysokiej elastyczności i sposoby ich zastosowania
ZA201801511B (en) Flavonoid compositions and methods of use
ZA201707981B (en) Compositions of obeticholic acid and methods of use
IL257307B (en) Transgenic crispr–cas9 preparations and methods of use
ZA201702794B (en) Cellulose-containing compositions and methods of making same
SG11201707876YA (en) Microalgal compositions and uses thereof
HUE056172T2 (hu) Szelenoorganikus vegyületeket tartalmazó készítmények és eljárások alkalmazásukra
ZA201906169B (en) Synthekine compositions and methods of use
ZA202104969B (en) Compositions comprising 15-hepe and methods of using the same
ZA201701909B (en) Trichoderma compositions and methods of use
SG11201708114SA (en) Ophthalmic compositions and methods of use therefor
SMT202200069T1 (it) Composizioni peptidiche e metodi di utilizzo
EP3190886A4 (en) Compositions and methods of use thereof
SG11201803284YA (en) Novel method of use and compositions
IL246711A0 (en) Biologically active haloperoxidase compositions and methods of using them
EP3207029A4 (en) Tryptamide compositions and methods of use
IL261794A (en) Preparations and methods for using them
IL247645A0 (en) Preparations of seleno-organic compounds and methods of using them
AU2014905067A0 (en) Compositions and methods of use
AU2014902829A0 (en) Compositions and Methods of Use